ImmunityBio, Inc. (IBRX)
| Market Cap | 1.86B |
| Revenue (ttm) | 7.33M |
| Net Income (ttm) | -587.79M |
| Shares Out | 696.83M |
| EPS (ttm) | -0.88 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,253,542 |
| Open | 2.750 |
| Previous Close | 2.780 |
| Day's Range | 2.575 - 2.760 |
| 52-Week Range | 2.500 - 10.530 |
| Beta | -0.43 |
| Analysts | Buy |
| Price Target | 17.38 (+549.72%) |
| Earnings Date | Nov 12, 2024 |
About IBRX
ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company’s platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including ... [Read more]
Financial Performance
In 2023, ImmunityBio's revenue was $622,000, an increase of 159.17% compared to the previous year's $240,000. Losses were -$583.20 million, 40.0% more than in 2022.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for IBRX stock is "Buy." The 12-month stock price forecast is $17.38, which is an increase of 549.72% from the latest price.
News
ImmunityBio: Forging A New Plan After Recent $100 Million Offering
ImmunityBio's recent $100M public offering was necessary to support ANKTIVA's commercialization and pipeline programs, despite the dilution and lower offering price of $3 per share. The company's cash...
ImmunityBio: Despite Share Price & Funding Woes, Muddy Path To Long-Term Success
ImmunityBio's Anktiva shows promise with potential peak revenues of ~$900m annually, but faces significant competition and financial challenges, including a poorly timed $100m fundraising effort. Desp...
D. Boral Capital Served as Co-Manager to ImmunityBio, Inc. (Nasdaq: IBRX) in connection with its $100.0 Million Underwritten Public Offering
CULVER CITY, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the pricing of its previously announced underwritten public of...
ImmunityBio, Inc. Announces Pricing of Public Offering of Common Stock
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the pricing of its previously announced underwritten public offering of an aggr...
ImmunityBio, Inc. Announces Proposed Public Offering of Common Stock
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that it intends to offer and sell, subject to market and other conditions, shar...
ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment
FREMONT, Calif. , Nov. 21, 2024 /PRNewswire/ -- ImmunityBio, Inc. (NASDAQ: IBRX), a vertically integrated biotechnology company, and nCartes, Inc., a transformational cloud software platform provider,...
ImmunityBio, Inc. Investor Alert (NASDAQ: IBRX): Schubert Jonckheer & Kolbe LLP Investigating Potential Shareholder Claims Against the Company's Officers and Directors for Possible False Statements
SAN FRANCISCO , Nov. 19, 2024 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP advises ImmunityBio, Inc. investors that the firm is investigating potential legal claims relating to the company's unsucce...
ImmunityBio Completes ANKTIVA's Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 Months
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced compelling new data from its ongoing QUILT 3.032 study. As of November 2024, 10...
ImmunityBio Reports Third-Quarter 2024 Financial Results
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) today announced its financial results for the third-quarter ended September 30, 2024. ANKTIVA® received a J-code (HCPCS Level II ...
ImmunityBio: CAR-NK Cell Therapy Data For NHL Expected In Second Half Of 2025
ImmunityBio's stock traded higher by 37% after dosing the first patient in its phase 1 QUILT 106 study for CD19+/CD20+ NHL, with data expected in 2025. The company's ANKTIVA therapy, combined with Key...
Top 2 Health Care Stocks That May Fall Off A Cliff This Month
As of Oct. 25, 2024, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
First Patients Dosed in Phase 1 Clinical Study of ImmunityBio's CAR-NK Cell Therapy for the Treatment of Relapsed B-Cell Non-Hodgkin Lymphoma
CULVER CITY, Calif.--(BUSINESS WIRE)--Immunotherapy innovator ImmunityBio, Inc. (NASDAQ: IBRX), announced today that the first patients have been dosed in an initial trial studying the potential of th...
800% Upside For This Biotech Stock - Analyst Initiates Coverage On Bladder Cancer Focused ImmunityBio
EF Hutton has initiated coverage on ImmunityBio Inc. IBRX, a vertically integrated biotechnology company developing therapies and vaccines to bolster the natural immune system for cancers and infectio...
ImmunityBio to Participate in the Jefferies London Healthcare Conference
CULVER CITY, Calif.--(BUSINESS WIRE)--Immunotherapy innovator ImmunityBio, Inc. (NASDAQ: IBRX), announced today that company executives will be participating in the Jefferies London Healthcare Confere...
ImmunityBio: Moving The Needle
ImmunityBio's ANKTIVA shows promising commercial and clinical progress, with expanded patient access and potential EU/UK regulatory filings, enhancing its global market penetration and revenue prospec...
ImmunityBio: Anktiva Launch, Good Data, Low Cash, High Debt
Anktiva, ImmunityBio's lead molecule, shows promising results with a 71% CR rate and 100% survival at 24 months for BCG-unresponsive NMIBC. Despite Anktiva's potential, ImmunityBio faces financial cha...
ImmunityBio Presents Positive Long-Term Overall Survival Data in Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA® and Checkpoint Immunotherapy at World Conference on Lung Cancer
CULVER CITY, Calif.--(BUSINESS WIRE)--Immunotherapy innovator ImmunityBio, Inc. (NASDAQ: IBRX), today announced positive results from its QUILT 3.055 trial demonstrating long-term extended survival of...
Top 3 Health Care Stocks That Are Set To Fly This Quarter
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
ImmunityBio: Anktiva's Launch Progresses - Bladder Cancer Drug May Be 'Real Deal'
ImmunityBio received FDA approval for ANKTIVA plus BCG for BCG-unresponsive bladder cancer in April. The drug has a unique mechanism of action. Immunity's early launch progress of Anktiva shows promis...
ImmunityBio's ANKTIVA® Now Covered By More Than a Dozen Insurance Plans Representing Over 100 Million Lives Within Months of FDA Approval
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), today announced significant progress in market access, making ANKTIVA® (nogapendekin alfa inbakicept-pmln) widely available to p...
ImmunityBio Announces Study of ANKTIVA® in Combination with the AdHER2DC Cancer Vaccine as a Potential Therapy to Control Endometrial Cancer
CULVER CITY, Calif.--(BUSINESS WIRE)--Immunotherapy company ImmunityBio, Inc. (NASDAQ: IBRX), today announced the opening of a clinical trial to study ANKTIVA® (nogapendekin alfa inbakicept-pmln) toge...
Kuehn Law Encourages Investors of ImmunityBio, Inc. to Contact Law Firm
NEW YORK , July 25, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of ImmunityBio, Inc. (NASDAQ: IBRX) breached their ...
ImmunityBio: Positive Near-Term Catalysts Create Strong Short Squeeze Potential
IBRX has a short interest % of the float of 33%, superior to GME at 21%. Investors should keep an eye on it for short squeeze-fueled volatility. IBRX has positive catalysts on the horizon, such as the...
ImmunityBio Announces Insurance Coverage of ANKTIVA® Across Multiple States with First Commercial Doses Administered Just Weeks After FDA Approval—Opening New Era for Immunotherapy Beyond Checkpoint Inhibitors
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) today announced the initial treatment of multiple patients in the United States to receive therapy with ANKTIVA® (nogapendekin al...
ImmunityBio Announces 2024 Annual Meeting of Stockholders with Company Update
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) announced today that its 2024 Annual Meeting of Stockholders will be held on Tuesday, June 11, 2024 at 9:30 a.m. Pacific Time. Th...